Viking Holdings Ltd (NYSE:VIK) shares slipped on Wednesday despite the cruise operator posting a strong second-quarter revenue jump and upbeat analyst commentary. The company reported an 18.5% year-over-year sales increase to $1.

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra bullish on VKTX stock.

Viking (NYSE: VIK) stock is down approximately 3% after the cruise line’s second-quarter earnings report. The company delivered revenue of $1.88 billion, ahead of the $1.84 billion analysts expected.

Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data were disappointing.

Viking? Royal Caribbean? Celebrity? What is Dan's favorite cruise line originally appeared on TravelHost. Everyone asks "what's your favorite cruise line?" It's a smart question, but there's no real answer. Realistically, it's really fun to be on a cruise.

Fair gates open at 10 a.m. and close at 10 p.m. weekdays and 11 p.m. weekends Friday, Aug. 22, through Monday, Sept. 1, Oregon State Fairgrounds, 2330 17th St. N.E. Salem; admission $3-$12, ages 5 and younger free; oregonstatefair.org.

We recently published 10 Stocks Hammered Harder Than Wall Street. Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of Tuesday’s worst performers. Viking Therapeutics fell by 42.12 percent on Tuesday to close at $24.

Viking Holdings Ltd. shares fell as the cruise line operator is facing constraints on how much it can charge for its journeys, suggesting its pricing power might be tapering off.